Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence.

@article{Lanitis2016CosteffectivenessOA,
  title={Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence.},
  author={Tereza Lanitis and Robert J Leipold and Melissa J Hamilton and Dale A. Rublee and Peter L. Quon and Chantelle Browne and Alexander A. Cohen},
  journal={Clinical therapeutics},
  year={2016},
  volume={38 3},
  pages={478-93.e1-16}
}
PURPOSE To assess the cost-effectiveness of apixaban versus rivaroxaban, low-molecular-weight heparin (LMWH)/dabigatran, and LMWH/vitamin K antagonist (VKA) for the initial treatment and prevention of recurrent thromboembolic events in patients with venous thromboembolism (VTE). METHODS A Markov model was developed to evaluate the pharmacoeconomic effect of 6 months of treatment with apixaban versus other anticoagulants over a lifetime horizon. Network meta-analyses were conducted using the… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 7 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.

Similar Papers

Loading similar papers…